Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

BeiGene Doses First Patient in China Phase I PARP Trial

publication date: Dec 22, 2016
BeiGene of Beijing has treated the first patient in China Phase I trial of BGB-290, a PARP inhibitor. The trial will administer BGB-290 to patients with advanced solid tumors. Two and a half years ago, BeiGene started its first trial of the drug in Australia, and it has reported positive early data from the test. One of the primary targets of BGB-290 will be ovarian cancer, and BeiGene also plans to pair the PARP inhibitor with its PD-1 immuno-oncology candidate in future trials. More details....

Stock Symbol: (NSDQ: BGNE)

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital